Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

27 avr. 2026 08h00 HE | Source: Humacyte, Inc

Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026

DURHAM, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at...
27 avr. 2026 08h00 HE | Source: Replimune, Inc.

Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

WOBURN, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...
27 avr. 2026 08h00 HE | Source: PharmAla Biotech

PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01

PharmAla signs a binding letter of intent to spin out its APA-01 novel asset into a joint venture with Aluvaris and Diteba, with deal to close in June.
27 avr. 2026 08h00 HE | Source: Avalyn Pharma Inc.

Avalyn Strengthens Leadership Team to Support Long-Term Growth with Appointments of Industry Leaders Adam Golden and Frank Salisbury

Avalyn Pharma strengthens leadership team with appointments of Adam Golden as General Counsel & Head of BD and Frank Salisbury as SVP, Commercial.
27 avr. 2026 08h00 HE | Source: BioVie, Inc.

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

CARSON CITY, Nev., April 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and...
27 avr. 2026 08h00 HE | Source: Pacira BioSciences

Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty

BRISBANE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the...
27 avr. 2026 07h41 HE | Source: Clearmind Medicine Inc.

Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation

Positive clinical results from Alcohol Use Disorder clinical trial may strengthen potential for eligibility for Breakthrough Therapy Designation Vancouver, Canada, April 27, 2026 (GLOBE NEWSWIRE)...
27 avr. 2026 07h30 HE | Source: Medicus Pharma Ltd

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development...
27 avr. 2026 07h18 HE | Source: Research and Markets

Insurance Third Party Administrators (TPAs) Global Market Report 2026: YoY Revenue Grew by $32 Billion - AI-Driven Claims Automation to Boost Insurance TPA Growth Through 2030

Dublin, April 27, 2026 (GLOBE NEWSWIRE) -- The "Insurance Third Party Administrators Market Report 2026" has been added to ResearchAndMarkets.com's offering. The insurance third-party...
27 avr. 2026 07h05 HE | Source: HBT Financial, Inc.

HBT Financial, Inc. Announces First Quarter 2026 Financial Results

HBT Financial, Inc. Announces First Quarter 2026 Financial Results

Page précédente

Page suivante